Please visit answersincme.com/ZZB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses available and emerging consolidation immunotherapies for the treatment of patients with unresectable stage III non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of approved and emerging consolidation immunotherapies in patients with unresectable stage III NSCLC; Identify factors that may inform the use of guideline-recommended and emerging consolidation immunotherapies in patients with unresectable stage III NSCLC; and Recognize the clinical significance of investigational approaches to the use of consolidation immunotherapy in unresectable stage III NSCLC.